Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0HMQLM
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
KHN922
|
|||||
| Synonyms |
KHN922
Click to Show/Hide
|
|||||
| Organization |
Kanghong Pharmaceutical (Originator)
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
7.5 (3.9+3.6)
|
|||||
|
|
||||||
| Antibody Name |
Patritumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-3 (ERBB3); Tumor-associated calcium signal transducer 2 (TACSTD2)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)+RNA polymerase II
|
Target Info | ||||
| Linker Name |
Mc-PEG2-VA-PAB+DBCO-PEG4-GGFG
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines+glycoside
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|